
Treatment for stomach cancer depends mostly on its stage and, for advanced disease, on biomarkers such as HER2. This Stomach Cancer Awareness Month explainer walks through the main options at each stage, based on National Cancer Institute guidance.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody. TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.
To read Janssen’s full press release






